NEUREN PHARMACEUTICALS LTD(NEU.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

NEU.AU NEUREN PHARMACEUTICALS LTD

Trading 05-01 14:22:22 AEST

19.13

-0.07

-0.36%

High19.35	Low18.71	Vol255.66K
Open18.76	D1 Closing19.20	Amplitude3.33%
Mkt Cap2.44B	Tradable Cap2.09B	Total Shares127.70M
T/O4.86M	T/O Rate0.23%	Tradable Shares109.21M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":19.13,"timestamp":1714537305045,"preClose":19.2,"halted":0,"volume":255658,"delay":0,"nameEN":"NEUREN PHARMACEUTICALS LTD","floatShares":109208662,"shares":127695676,"eps":1.201,"marketStatus":"Trading","change":-0.07,"latestTime":"05-01 14:22:22 AEST","open":18.76,"high":19.35,"low":18.71,"amount":4863772,"amplitude":0.033333,"askPrice":19.14,"askSize":177,"bidPrice":19.13,"bidSize":119,"shortable":3,"etf":0,"ttmEps":1.201,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1714543200000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":19.2,"openAndCloseTimeList":[[1714521600000,1714543200000]],"volumeRatio":1.117576,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/NEU.AU","defaultTab":"news","newsList":[{"id":"2432559328","title":"Backed by industry titans, this fundie is leveraging Australia's healthcare innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2432559328","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2432559328?lang=en_us&edition=fundamental","pubTime":"2024-05-01 07:30","pubTimestamp":1714519806,"startTime":"0","endTime":"0","summary":"Name of the fund: KP Rx Healthcare Opportunities Fund. Description of strategy: A closed-ended VC fund designed to strategically invest in the most promising healthcare and health-tech companies across ANZ, targeting both private and early-stage public companies at the inflection point of valuation creation. Investment objective: Target net IRR of 20% over the life of the fund. Aim to return the majority of the capital 4-6 years into the fund's life, with a formal 10-year cap providing flexibility to unlock greater value by investing in companies that benefit from staying private longer.That’s the profile of Hashan De Silva, who is launching the KP Rx Healthcare Opportunities Fund. Whilst we wouldn't normally profile a fund manager's background and track record this way, it provides important context as it has attracted some of Australia’s most successful healthcare entrepreneurs who are backing the fund as investors, including;Much simpler ethics approvals and governance: In Australia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/backed-by-industry-titans-this-fundie-is-leveraging-australia-s-healthcare-innovation","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/backed-by-industry-titans-this-fundie-is-leveraging-australia-s-healthcare-innovation","is_publish_highlight":false,"gpt_icon":0},{"id":"2430823027","title":"RS, RYAM and NMG are among materials movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2430823027","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2430823027?lang=en_us&edition=fundamental","pubTime":"2024-04-26 02:16","pubTimestamp":1714068981,"startTime":"0","endTime":"0","summary":"More on Materials Sector  XLB Surges To The Sector-Performance Lead, More Upside Likely Albemarle remains the most heavily shorted materials stock in March Steel Dynamics, Dow among top materials picks ahead of Q1 earnings; Albemarle gets a Sell Seeking Alpha’s Quant Rating on Materials Select Sector SPDR ETF Dividend scorecard for Materials Select Sector SPDR ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4094387-rs-ryam-and-nmg-are-among-materials-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2430230178","title":"NewMarket on Pace for Largest Percent Decrease Since February 2022 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2430230178","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2430230178?lang=en_us&edition=fundamental","pubTime":"2024-04-26 02:16","pubTimestamp":1714068960,"startTime":"0","endTime":"0","summary":"NewMarket Corporation  is currently at $549.04, down $34.21 or 5.87%. --Would be lowest close since Jan. 2, 2024, when it closed at $547.69. --On pace for largest percent decrease since Feb. 3, 2022, when it fell 11.11%. --Currently down three consecutive days; down 6.71% over this period. --Down 13.49% month-to-date; on pace for worst month since Feb. 2012, when it fell 15.62%. --Down 14.73% from its all-time closing high of $643.89 on March 1, 2024. --Up 38.81% from 52 weeks ago , when it closed at $395.52. --Up 40.84% from its 52-week closing low of $389.82 on May 31, 2023. --Traded as low as $542.73; lowest intraday level since Jan. 3, 2024, when it hit $542.32. --Down 6.95% at today's intraday low; largest intraday percent decrease since Feb. 3, 2022, when it fell as much as 11.6%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2429129081","title":"Where are they now? The 10 biggest gainers in the ASX 200 last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2429129081","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2429129081?lang=en_us&edition=fundamental","pubTime":"2024-04-24 07:23","pubTimestamp":1713914586,"startTime":"0","endTime":"0","summary":"There’s a saying which has been popularised in movies like Mad Max: “One day you’re cock of the walk, the next, you’re a feather duster”. It’s the equivalent of ‘past performance is no reliable indicator of future performance’ which is imprinted in my brain from years working in a bank, let alone with fund managers today.If there was a year to worry about the so-called ‘cock of the walks’, 2023 would probably stand high with AI fuelling the extraordinary success of the Magnificent Seven. Despite that, many contributors to Livewire have suggested there is more to come – at least for the time being.But while that might cover off the biggest hitters globally, what about closer to home?It’s only a few months ago, but do you remember who the biggest gainers on the ASX200 were in 2023?My colleague Kerry Sunhas crunched the numbers for me and pulled the 10 biggest gainers as at 29 December 2023.The 10 biggest gainers of the ASX200 as at end 2023","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/where-are-they-now-the-10-biggest-gainers-in-the-asx-200-last-year","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/where-are-they-now-the-10-biggest-gainers-in-the-asx-200-last-year","is_publish_highlight":false,"gpt_icon":0},{"id":"2429044181","title":"BRIEF-Neuren Pharmaceuticals Says Trofinetide New Drug Submission For Rett Syndrome Accepted For Priority Review By Health Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2429044181","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2429044181?lang=en_us&edition=fundamental","pubTime":"2024-04-23 09:22","pubTimestamp":1713835367,"startTime":"0","endTime":"0","summary":"April 23 (Reuters) - Neuren Pharmaceuticals Ltd :   * TROFINETIDE NEW DRUG SUBMISSION FOR RETT SYNDROME ACCEPTED FOR PRIORITY REVIEW BY HEALTH CANADAFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426477456","title":"How your #1 stock tips fared in Q1 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2426477456","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2426477456?lang=en_us&edition=fundamental","pubTime":"2024-04-11 10:00","pubTimestamp":1712800829,"startTime":"0","endTime":"0","summary":"As the market continues to confound by staying at record highs, some of the top local sectors in the first quarter were Technology, Real Estate and Financials. Two of these featured among the stocks that you, our valued readers, named as your top tips for 2024 in our Outlook Series reader survey .In the following table, we recap the full list of companies you selected and weigh their performance in the first quarter of 2024.Read on to find out which names across the Commodities, Healthcare  and Consumer Discretionary sectors topped the table – and also some of those that lagged.For the top five performers, we also delve into some of the most recent professional investor commentary featured on Livewire Markets.This demand is spurred by the growing realisation that developed nations need to embrace nuclear fuel if they’re to come anywhere near hitting their aggressive carbon emission reduction targets. That’s why we saw the US, Canada, UK, and Japan among 22 nations that committed to tri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/how-your-1-stock-tips-fared-in-q1-2024","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/how-your-1-stock-tips-fared-in-q1-2024","is_publish_highlight":false,"gpt_icon":0},{"id":"2424671079","title":"3 ASX shares to help turn $100,000 into $1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2424671079","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2424671079?lang=en_us&edition=fundamental","pubTime":"2024-04-03 03:00","pubTimestamp":1712084400,"startTime":"0","endTime":"0","summary":"Turning $100,000 into a million bucks might sound like magic. But no one needs supernatural powers if they use ASX shares and compounding to their advantage. Allow me to introduce you to three stocks that I reckon could do the trick: Temporary glitch, with long-term tailwinds still there Johns Lyng Group Ltd  is an insurance claims repairer that has been a favourite of professional investors for years now. And why not?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/03/3-asx-shares-to-help-turn-100000-into-1-million/","is_publish_highlight":false,"gpt_icon":0},{"id":"2424741912","title":"Top ASX shares to buy in April 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2424741912","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2424741912?lang=en_us&edition=fundamental","pubTime":"2024-04-01 01:00","pubTimestamp":1711904400,"startTime":"0","endTime":"0","summary":"If you've been a bunny and missed out on the 3.45% gains already delivered by the S&P/ASX 200 Index so far in 2024, fear not!","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/01/top-asx-shares-to-buy-in-april-2024/","is_publish_highlight":false,"gpt_icon":0},{"id":"2422794963","title":"1 secretly cheap ASX 200 stock I'm buying for the long run","url":"https://stock-news.laohu8.com/highlight/detail?id=2422794963","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2422794963?lang=en_us&edition=fundamental","pubTime":"2024-03-28 01:30","pubTimestamp":1711560600,"startTime":"0","endTime":"0","summary":"When an S&P/ASX 200 Index  stock outperforms all and sundry one year but then suddenly dips, you need to at least check out what's happening. Neuren Pharmaceuticals Ltd  was the highest climber in the ASX 200 last year, gaining an insane 214% over the calendar year. But a reality check has been delivered for investors this year, with an 18.6% tumble so far. So what's doing?Is this a bargain just waiting to be bought?Why has Neuren become a cheap ASX stock?So is this a value trap or a golden opportunity to buy into a fast-growing company for dirt cheap?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/03/28/1-secretly-cheap-asx-200-stock-im-buying-for-the-long-run/","is_publish_highlight":false,"gpt_icon":0},{"id":"2421028121","title":"3 ASX stocks boasting better margins than Nvidia","url":"https://stock-news.laohu8.com/highlight/detail?id=2421028121","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2421028121?lang=en_us&edition=fundamental","pubTime":"2024-03-21 23:30","pubTimestamp":1711035000,"startTime":"0","endTime":"0","summary":"The green graphics card giant is making a motza. But did you know some ASX companies have even bigger profit margins than Nvidia Corp ?Masterfully riding the AI wave, Nvidia looks like the Kelly Slater of computer hardware. The insatiable hunger for AI-enabling chips is fattening the technology company's profits. For 12 months ended January 2024, this A$3.4 trillion business pulled a 48.8% net margin.I'm talking margin monsters like Nvidia on our local ASX bourse.There are 43 ASX-listed stocks with superior margins to Nvidia. However, I wouldn't count some of these due to quirky accounting practices. Still, if thick profit margins are your jam, plenty of options exist.67% net margin: Any business that collects a royalty on something usually operates on high margins. There are minimal costs to eat away at the revenue gathered from sales. Deterra Royalties Ltd  is a locally-listed company relishing in this situation.In the 12 months ended 31 December 2023, Neuren reached $231.9 million i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/03/22/3-asx-stocks-boasting-better-margins-than-nvidia/","is_publish_highlight":false,"gpt_icon":0},{"id":"2420284943","title":"The best ASX shares to invest $500 in right now","url":"https://stock-news.laohu8.com/highlight/detail?id=2420284943","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2420284943?lang=en_us&edition=fundamental","pubTime":"2024-03-19 03:30","pubTimestamp":1710790200,"startTime":"0","endTime":"0","summary":"Market is telling you that it's exciting about its future and that it's essential in AI. \"Half of its revenue is from NSW and ACT — hu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/03/19/the-best-asx-shares-to-invest-500-in-right-now/","is_publish_highlight":false,"gpt_icon":0},{"id":"2418305589","title":"ASX 200 delivers dead cat bounce, gold and tech stocks best, coal stocks slump","url":"https://stock-news.laohu8.com/highlight/detail?id=2418305589","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2418305589?lang=en_us&edition=fundamental","pubTime":"2024-03-12 16:17","pubTimestamp":1710231443,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200  finished 8.3 points higher at 7,712.5, 0.31% from its session high and just 0.15% from its low. In the broader-based S&P/ASX 300 , advancers beat decliners by an impressive 173 to 98.The Gold   sub-index was the best performing sector today. Nothing specific here, gold prices are roughly flat. I do note Newmont Corporation   was up nearly 4% last night on the NYSE, and the US-listed gold sector was also generally higher.Also doing well today was the Information Technology  . Tech has just been so solid since the October low, and this strength is hard to shake in a market with few growth alternatives. The majors of Wisetech Global  , Xero   and Life360   contributed most of the index points, but there were several other commendable performances.Tech stocks were once again well represented in the winners list. Coal stocks featured in the XEJ's biggest losers list. Unfortunately, thermal coal futures aren't looking much better than coking coal fut","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/asx-200-delivers-dead-cat-bounce-gold-and-tech-stocks-best-coal-stocks-slump","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/asx-200-delivers-dead-cat-bounce-gold-and-tech-stocks-best-coal-stocks-slump","is_publish_highlight":false,"gpt_icon":0},{"id":"2418438367","title":"$10k of savings? I'd buy these ASX 200 shares to grow my money","url":"https://stock-news.laohu8.com/highlight/detail?id=2418438367","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2418438367?lang=en_us&edition=fundamental","pubTime":"2024-03-12 00:00","pubTimestamp":1710172800,"startTime":"0","endTime":"0","summary":"If you have $10,000 to invest right now, there are some excellent S&P/ASX 200 Index (ASX: XJO) stocks that can grow that money. When choosing stocks, I take the view of whether that cash will be inves","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/03/12/10k-of-savings-id-buy-these-asx-200-shares-to-grow-my-money/","is_publish_highlight":false,"gpt_icon":0},{"id":"2417181473","title":"Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically","url":"https://stock-news.laohu8.com/highlight/detail?id=2417181473","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2417181473?lang=en_us&edition=fundamental","pubTime":"2024-03-06 04:41","pubTimestamp":1709671297,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals Limited ( ASX:NEU ) shareholders will have a reason to smile today, with the analysts making...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/forecast-analysts-think-neuren-pharmaceuticals-limiteds-asxn","is_publish_highlight":false,"gpt_icon":0},{"id":"2417442685","title":"4 Australian shares set to soar in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2417442685","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2417442685?lang=en_us&edition=fundamental","pubTime":"2024-03-06 02:30","pubTimestamp":1709663400,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index  might have risen four months straight, but many experts are still bullish about the rest of 2024.Shaw and Partners portfolio manager James Gerrish said in his newsletter that his team is \"bullish equities through 2024/5\".\"The ASX is stronger than many probably give it credit for.\"If/when the resources sector enjoys a bid, the ASX 200 will be knocking on the 8000 door. e.g. The index's largest stock, BHP Group Ltd , is still trading over 13% below its 2024 high.\". So in this upbeat environment, which Australian shares are best set to elevate to the next level?Mader Group Ltd  is a maintenance contractor for clients in the mining industry.Like Gerrish mentioned, the resources sector is in a low part of its cycle at the moment, so Mader shares are also down about 19% since September.But that gives it a low base off which to jump in 2024.A short seller attack on Neuren Pharmaceuticals Ltd  has seen its share price plummet almost 21% so far this year.The resurgence of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/03/06/4-australian-shares-set-to-soar-in-2024/","is_publish_highlight":false,"gpt_icon":0},{"id":"2416156899","title":"Leading brokers name 3 ASX shares to buy today","url":"https://stock-news.laohu8.com/highlight/detail?id=2416156899","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2416156899?lang=en_us&edition=fundamental","pubTime":"2024-03-04 12:22","pubTimestamp":1709526175,"startTime":"0","endTime":"0","summary":"With so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/03/04/leading-brokers-name-3-asx-shares-to-buy-today-245/","is_publish_highlight":false,"gpt_icon":0},{"id":"2416998307","title":"Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2416998307","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2416998307?lang=en_us&edition=fundamental","pubTime":"2024-03-02 08:57","pubTimestamp":1709341071,"startTime":"0","endTime":"0","summary":"The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/heres-why-neuren-pharmaceuticals-asxneu-has-caught-the-eye-o","is_publish_highlight":false,"gpt_icon":0},{"id":"2416603157","title":"Are Robust Financials Driving The Recent Rally In Neuren Pharmaceuticals Limited's (ASX:NEU) Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2416603157","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2416603157?lang=en_us&edition=fundamental","pubTime":"2024-03-02 06:21","pubTimestamp":1709331682,"startTime":"0","endTime":"0","summary":"Most readers would already be aware that Neuren Pharmaceuticals'  stock increased significantly by 22% over the past three months. Given the company's impressive performance, we decided to study its financial indicators more closely as a company's financial health over the long-term usually dictates market outcomes. In this article, we decided to focus on Neuren Pharmaceuticals'  ROE.Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Put another way, it reveals the company's success at turning shareholder investments into profits.Check out our latest analysis for Neuren Pharmaceuticals. Return on equity can be calculated by using the formula:. Return on Equity = Net Profit  ÷ Shareholders' Equity. So, based on the above formula, the ROE for Neuren Pharmaceuticals is:. Neuren Pharmaceuticals doesn't pay any dividend to its shareholders, meaning that the company has been reinvesting all","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/robust-financials-driving-recent-rally-222122302.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2416271976","title":"Which ASX shares delivered the biggest profit jumps of the earnings season?","url":"https://stock-news.laohu8.com/highlight/detail?id=2416271976","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2416271976?lang=en_us&edition=fundamental","pubTime":"2024-03-02 03:30","pubTimestamp":1709321400,"startTime":"0","endTime":"0","summary":"With earnings season nearing an end, we showcase 12 ASX shares that delivered some of the best profit boosts this season.  In some cases, these mega profit gains led to significantly increased dividends for ASX investors, too.  Which ASX shares delivered the biggest profit increases?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/03/02/which-asx-shares-delivered-the-biggest-profit-jumps-of-the-earnings-season/","is_publish_highlight":false,"gpt_icon":0},{"id":"2415564106","title":"What's with the Neuren Pharmaceuticals share price today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2415564106","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2415564106?lang=en_us&edition=fundamental","pubTime":"2024-02-29 15:42","pubTimestamp":1709192538,"startTime":"0","endTime":"0","summary":"The Neuren Pharmaceuticals share price recorded the strongest growth of any ASX 200 stock in 2023.  Neuren shares ripped up the charts, gaining 214% over the 12 months to 31 December.  Most of that gain came on the back of FDA approval and the initial sales success of Daybue, which is a world-first drug treatment for Rett syndrome. The Neuren share price surged again in December after the company released top-line resultsfrom its Phase 2 clinical trial of NNZ-2591 in children with the debilitating Phelan-McDermid syndrome .  There are currently no approved treatments for PMS. According to the release, a significant improvement was observed by both clinicians and caregivers from treatment during the trial.   What did management say?Neuren Pharmaceuticals has been under pressure over the past fortnight since a US short-seller released a report describing Daybue as a \"flop\" amid \"horror stories\" of side effects among patients.  The short seller's report was released in the US on 15 Februa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/02/29/whats-with-the-neuren-pharmaceuticals-share-price-today/","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurenpharma.com","stockEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":-0.0952},{"period":"3month","weight":-0.1871},{"period":"6month","weight":0.7006},{"period":"1year","weight":0.3913},{"period":"ytd","weight":-0.2311}],"compareEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0179},{"period":"3month","weight":0.0642},{"period":"6month","weight":0.1296},{"period":"1year","weight":0.0892},{"period":"ytd","weight":0.091}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as is in Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591 that is in preclinical development for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Camberwell, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.315789,"avgChangeRate":-0.052499},{"month":2,"riseRate":0.35,"avgChangeRate":-0.043889},{"month":3,"riseRate":0.5,"avgChangeRate":0.37497},{"month":4,"riseRate":0.368421,"avgChangeRate":0.006181},{"month":5,"riseRate":0.315789,"avgChangeRate":-0.045376},{"month":6,"riseRate":0.684211,"avgChangeRate":0.111382},{"month":7,"riseRate":0.315789,"avgChangeRate":-0.047153},{"month":8,"riseRate":0.421053,"avgChangeRate":0.013904},{"month":9,"riseRate":0.631579,"avgChangeRate":0.130929},{"month":10,"riseRate":0.631579,"avgChangeRate":0.084928},{"month":11,"riseRate":0.473684,"avgChangeRate":0.038496},{"month":12,"riseRate":0.315789,"avgChangeRate":0.025797}],"exchange":"ASX","name":"NEUREN PHARMACEUTICALS LTD","nameEN":"NEUREN PHARMACEUTICALS LTD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NEUREN PHARMACEUTICALS LTD(NEU.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NEUREN PHARMACEUTICALS LTD(NEU.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NEUREN PHARMACEUTICALS LTD,NEU.AU,NEUREN PHARMACEUTICALS LTD股票,NEUREN PHARMACEUTICALS LTD股票老虎,NEUREN PHARMACEUTICALS LTD股票老虎国际,NEUREN PHARMACEUTICALS LTD行情,NEUREN PHARMACEUTICALS LTD股票行情,NEUREN PHARMACEUTICALS LTD股价,NEUREN PHARMACEUTICALS LTD股市,NEUREN PHARMACEUTICALS LTD股票价格,NEUREN PHARMACEUTICALS LTD股票交易,NEUREN PHARMACEUTICALS LTD股票购买,NEUREN PHARMACEUTICALS LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NEUREN PHARMACEUTICALS LTD(NEU.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NEUREN PHARMACEUTICALS LTD(NEU.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction